Research and InnovationResearch Radar
Group therapy with psilocybin may reduce depression in people with cancer
Psychedelic-assisted psychotherapy is typically offered in a private setting, involving one patient and two therapists. A...
By João L. de Quevedo, MD, PhD
Published on · Last reviewed on · 3 min read
Psychedelic-assisted psychotherapy is typically offered in a private setting, involving one patient and two therapists. A small study described today in Cancer suggests that a single session of psilocybin-assisted therapy, delivered in a group setting, may significantly reduce depressive symptoms in patients with cancer for up to eight weeks, with minimal side effects.
“Approximately 25% to 33% of patients with cancer meet criteria for clinically significant depressive symptoms, which are associated with lower treatment adherence, reduced quality of life, and higher mortality rates,” wrote Manish Agrawal, M.D., CEO and cofounder of Sunstone Therapeutics in Rockville, Maryland, and colleagues. Partial funding for this trial was provided by Compass Pathways, and some of the authors of the report in Cancer own stock in Compass Pathways.
For the open-label study, the researchers recruited adults with cancer and major depression. Adults with depression with psychotic features and/or suicidal thoughts were excluded, as were those taking antidepressants, antipsychotics, and/or medical cannabis. Participants with both curable and incurable cancer were included in the study.
A total of 30 participants (mean age 56 years, predominantly women) were divided into groups of three or four people. All groups received the following:
A two-hour individual therapy session, during which participants met their assigned therapist and were informed about what to expect from psilocybin therapy and about coping strategies.
A two-hour session on the day before psilocybin treatment. This included a 45-minute individual session with the therapist to set an intention and a 75-minute group psychoeducation component.
A psilocybin session (lasting 6 to 7 hours), during which participants in each group simultaneously received 25 mg of psilocybin while in individual rooms with their assigned therapist. Participants were separated from the other group participants by sliding doors without soundproofing.
Two two-hour post-treatment integration sessions one week apart. These sessions included a 45-minute individual component and a 75-minute group component.
The participants’ mean score on the Montgomery-Åsberg Depression Rating Scale (MADRS) at baseline was 25.9, indicating moderate depression. Three weeks after psilocybin treatment, mean MADRS scores fell by more than 19 points in the group, and this improvement was maintained 8 weeks after psilocybin administration.
Half of the participants no longer met DSM-5 criteria for major depression at week 8. Patients also reported significant improvements in their anxiety symptoms after psilocybin-assisted therapy.
Agrawal and colleagues noted that this new protocol did not result in any serious adverse events in participants. The most common treatment-related side effects were nausea and headaches, which were generally mild and are known side effects of psilocybin.
“This innovative framework offers greater scalability and dissemination of psilocybin treatment in real-world settings and alleviates the costs and time burdens of using two therapists for one patient,” wrote Agrawal and colleagues.
“If group-based approaches can improve treatment outcomes and save costs compared with individually assisted psychedelic therapy, they will be an important innovation in making these treatments more accessible and ensuring that as many patients as possible can benefit from their healing potential,” wrote Johannes Thrul, Ph.D., of the Johns Hopkins Bloomberg School of Public Health and colleagues in an accompanying editorial. However, the “potential for participants in a group to influence one another in beneficial or harmful ways” should be considered an important limitation when examining these results, they added.
To read more on this topic, see the Psychiatric News article “Depression Improves After a Single Dose of Psilocybin.”
Related content
Research and Innovation
UTHealth Houston Opens Recruitment for the RESONATE Trial: Investigating a New Approach to Brain Stimulation for Depression
The Center for Interventional Psychiatry at UTHealth Houston has been activated for the RESONATE clinical trial, which investigates an emerging form of brain stimulation for adults living with treatment-resistant depression.
· Article
Mood Disorders
The Intersection of Depression and ASD
Depression is a heavy burden for anyone, but for individuals on the autism spectrum, its weight can be particularly...
· Article
News
FDA Approves Zuranolone for Postpartum Depression
In a groundbreaking moment for mental health, the Food and Drug Administration (FDA) recently approved zuranolone, a new medication,...
· Research Radar